MIRA INFORM REPORT
|
Report Date : |
24.03.2011 |
IDENTIFICATION DETAILS
|
Name : |
BEIJING KINGHAWK PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
05.07.1996 |
|
|
|
|
Com. Reg. No.: |
110302004649474 |
|
|
|
|
Legal Form : |
Shares Limited Company |
|
|
|
|
Line of Business : |
Researching
& Developing, Manufacturing and selling pharmaceutical products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 500,000 |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
|
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
BEIJING KINGHAWK
PHARMACEUTICAL CO., LTD.
NO. 7 YUNCHENG STREET,
TEL: 86 (0) 10-67878866 FAX: 86 (0) 10-67880632
EXECUTIVE SUMMARY
INCORPORATION DATE : JUL.
5, 1996
REGISTRATION NO. : 110302004649474
REGISTERED LEGAL FORM : SHARES LIMITED CO.
STAFF STRENGTH :
121
REGISTERED CAPITAL : CNY 42,000,000
BUSINESS LINE :
R&D, MANUFACTURE, TRADE
TURNOVER :
CNY 61,580,000 (UNAUDITED, AS OF
DEC. 31, 2010)
EQUITIES :
CNY 74,220,000 (UNAUDITED, AS OF DEC. 31, 2010)
PAYMENT :
AVERAGE
RECOMM.
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION : FAIRLY GOOD
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE : CNY 6.56 = USD 1
Adopted abbreviations
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY -
SC was registered as a shares limited co. at local Administration for
Industry & Commerce (AIC - The official body of issuing and renewing
business license).
Company Status: Shares Limited Co. This form of business in PR China
is defined as a legal person. Its registered capital is divided into shares
of equal par value and the co. raises capital by issuing share certificates
by promotion or by public offer. Shareholders bear limited liability to the
extent of shareholding, and the co. is liable for its debts only to the
extent of its total assets. The co has independent property of legal person
and enjoys property rights of legal person. The characteristics of
the shares limited co. are as follows: The establishment of the co.
requires at least two promoters and no more than 200, half of whom shall be
domiciled in The minimum registered capital
of a co. is CNY The
board of directors must consist of five to nineteen directors. If the co. raises capital by public
offer, the promoters must not subscribe less than 35% of the total shares.
the promoters’ shares are restricted to transfer- within one year of the
offer. A
state-owned enterprise that is restructured into a shares limited co. must
comply with the conditions &
requirements specified under the law & administrative rule.
SC’s registered business scope includes manufacturing IVD Reagents;
researching & developing, consultation and service on biotechnology;
selling Category II clinical test analysis instrument and diagnostic reagent, Category
II medical tests and basic equipment, ordinary diagnosis instrument, medical
cold therapy & low temperature refrigeration equipment and appliance,
hardware & electric and chemical products (excluding hazardous chemicals),
native products, computer and its parts, daily cosmetics.
SC is mainly
engaged in researching & developing, manufacturing and selling
pharmaceutical products.
Mr.
Zhang Zhi is legal representative and
chairman of SC at present.
SC is known to
have approx. 121 employees at present.
SC
is currently operating at the above stated address, and this address houses its
operating office and factory in the economic & technology development zone
of Beijing. Our checks reveal that SC owns the total premise with an area of
about 6,000 square meters.
http://www.kinghawk828.com/
the design is professional and the content is well-organized. At present it is
in both English and Chinese versions.
E-mail: market@kinghawk828.com
Certificates:
ISO13485: 2003
ISO9001: 2000
Medicine GMP Certificate
MAIN
SHAREHOLDERS:
Name
%
of Shareholding
Zhang Zhi 50
Cao Jianrong 50
l
Legal Representative and Chairman:
Mr.
Working Experience(s):
At present Working in SC as legal representative and chairman.
l
Vice Chairman and General Manager:
Ms.
Working Experience(s):
At present Working in SC as vice chairman and general manager.
l
Directors:
Dai Zhicheng ID# 510102193611116136
Guo Jianbao ID# 371100197401090513
Ni Daoming ID# 11010519410525413X
l
Supervisors:
Liu Xingwang ID# 610121197310313073
Niu Gaiyun ID# 410782197609245325
Yu Xinbo ID# 412924197709011330
SC is mainly
engaged in researching & developing, manufacturing and selling
pharmaceutical products.
SC’s products mainly include: Many genetic engineering antigen,
monoclonal antibody, enzyme-linked immuno sorbent assay, Immune rapid diagnosis
reagent, Molecular diagnostic reagents, Type reagent, biochemical reagents,
etc.
SC sources its materials 100% from domestic market. SC sells its
products 90% in domestic market, and 10% to overseas market.
The buying terms of SC include Check, T/T and Credit of 30-60 days. The
payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Note: SC refused
to release its major suppliers and customers.
SC
is not known to have any subsidiary at present.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not provide any name of trade/service
suppliers and we have no other sources to conduct the enquiry at present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for collection
within the last 6 years.
China
Construction Bank
AC#:
11001029500056033230
Relationship:
Balance Sheet
|
Unit: CNY’000 |
as of Dec. 31,
2010 (unaudited) |
|
Cash & bank |
6,220 |
|
Inventory |
20,280 |
|
Notes receivable |
840 |
|
Accounts
receivable |
11,210 |
|
Advances to
supplies |
1,550 |
|
Other
receivables |
5,790 |
|
Subsidies
receivable |
0 |
|
Prepaid expenses |
0 |
|
Other current
assets |
0 |
|
|
------------------ |
|
Current assets |
45,890 |
|
Fixed assets net
value |
27,410 |
|
Projects under
construction |
590 |
|
Long-term
investments |
0 |
|
Intangible
assets |
5,250 |
|
Deferred tax
assets |
500 |
|
Other assets |
0 |
|
|
------------------ |
|
Total assets |
79,640 |
|
|
============= |
|
Short loans |
0 |
|
Accounts payable |
3,540 |
|
Advances from
customers |
0 |
|
Notes payable |
0 |
|
Wages payable |
280 |
|
Welfares payable |
0 |
|
Taxes payable |
830 |
|
Other accounts
payable |
0 |
|
Other current
liabilities |
10 |
|
|
----------------- |
|
Current
liabilities |
4,660 |
|
Specified
payables |
600 |
|
Anticipation
liabilities |
160 |
|
Other long term
liabilities |
0 |
|
|
------------------ |
|
Total
liabilities |
5,420 |
|
Shareholders
equities |
74,220 |
|
|
------------------ |
|
Total
liabilities & equities |
79,640 |
|
|
============= |
Income Statement
|
Unit: CNY’000 |
as of Dec. 31,
2010 (unaudited) |
|
Turnover |
61,580 |
|
Cost of goods sold |
24,310 |
|
Sales expense |
13,040 |
|
Management expense |
9,330 |
|
Finance expense |
130 |
|
Profit before
tax |
20,000 |
|
Less: profit tax |
2,940 |
|
Profits |
17,060 |
Important Ratios
=============
|
|
as of Dec. 31,
2010 |
|
*Current ratio |
9.85 |
|
*Quick ratio |
5.50 |
|
*Liabilities
to assets |
0.07 |
|
*Net profit margin
(%) |
27.70 |
|
*Return on
total assets (%) |
21.42 |
|
*Inventory
/Turnover ×365 |
121days |
|
*Accounts
receivable/Turnover ×365 |
67
days |
|
*Turnover/Total
assets |
0.77 |
|
* Cost of
goods sold/Turnover |
0.39 |
PROFITABILITY:
FAIRLY GOOD
l
The turnover of SC appears average in its line.
l
SC’s net profit margin is good.
l
SC’s return on total assets is good.
l
SC’s cost of goods sold is low, comparing with its
turnover.
LIQUIDITY: AVERAGE
l
The current ratio of SC is maintained in a normal
level.
l
SC’s quick ratio is maintained in a normal level.
l
The inventory of SC is fairly large.
l
The accounts receivable of SC is average.
l
SC has no short term loan in 2010.
l
SC’s turnover is in a fair level, comparing with
the size of its total assets.
LEVERAGE: FAIRLY
GOOD
l
The debt ratio of SC is low.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly Good.
SC is considered medium-sized in its line with fairly good financial
conditions. The given credit amount would appear to be within SC’s capacities.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.96 |
|
|
1 |
Rs.73.57 |
|
Euro |
1 |
Rs.63.68 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.